Wilms tumor in Costa Rican children
DOI:
https://doi.org/10.51481/amc.v60i1.987Keywords:
Wilms tumor, renal tumor, pediatrics, treatment, global survival, clinical characteristics, disease-free survivalAbstract
Objective: to describe the clinical characteristics of the group of children diagnosed with Wilms' tumor in Costa Rica and what was the clinical evolution according to the different treatments received in the Oncohematology Division of the National Children's Hospital.
Methods: this is a retrospective descriptive study that analyzed the patients with diagnosis of Wilms tumor confirmed by biopsy in period of 20 years. We reviewed 69 records of patients aged between 0 and 13 years, in which the clinical, therapeutic (chemotherapy, radiotherapy) and prognostic data (global and disease-free survival) of each one were analyzed.
Results: a total sample of 69 cases was analyzed. Among the results, it was found that the patients presented an average age of 41.3 months at the moment of diagnosis. The average follow-up was 7.4 years. The presence of an abdominal mass was the predominant clinical finding (55%). In addition, stage III was the most common (31.8%). Total nephrectomy without tumor rupture was the surgical procedure in the majority of cases. 80% of the patients presented favorable histology in the histopathological analysis. In 51% of cases, pre-surgical chemotherapy was used. 17% of the patients presented pulmonary metastasis. Overall survival was 73.3% and disease free survival was 69%.
Conclusions: Costa Rican patients with localized Wilms' tumor had poorer results than that of patients in developed countries, but the survival was similar in metastatic cases.
Downloads
References
Al-Hussain T, Ali A, Ahktar M. Wilms Tumor: an update. Adv Anat Pathol 2014;21:166-173
Breslow N. Olshan A. Beckwith B. Green D. Epidemiology of Wilms tumor. Med Pediatr Oncol 1993;21:172-181
Varan A. Wilms tumor in children: an overview. Nephron Clin Pract 2008;108: 83-90
Fischbach BV. Trout Kl. Lewis J. Luis CA. Ski M. WAGR syndrome: a clinical of 54 cases. Pediatrics. 2005; 116,984-8
E. Ko Michael, Ritchey M. Current management of Wilms tumor in children. J Ped Uro. 2009; 56-65
Siegel MJ, Chung EM. Wilms tumor and other pediatric renal masses. Magn Reson Imaging Clin N Am 16 2008; 479-497
Erginel B, Vural S, Akin M, Karadag C, Sever N, Abdullah et al. Wilms Tumor: A 24 year retrospective study from a single center. J Pediatr Hematol Onco, 2014; 31:409-414
Ching Ching C, Ka Fan T, Hui Keung Y, Kwok Shing Chiang A, Cheung Ling S, Chau Ho Fi, et al. A 20 year prospective study of Wilms tumor and other kidney tumors: a report from Hong Kong. J Pediatr Hematol Oncol 2014; 36:445-450
Meléndez Mambié M, Guibelalde del Castillo M, Nieto del Rincón N, Jimenez R, Femenia R, Piñana R. Tumor de Wilms bilateral metacrónico. An Esp Pediatr. 2002; 241-250.
Vujanic G. Renal tumor of childhood: an overview. Diagn Histopathol 2009:15:11 501-509
Keebsabai S. Jurairut T. Achar S. Long-Term outcome in pediatric renal tumor survivors: experience of a single center. J Pediatr Hematol Oncol 2013: 35, 610-613.
Bhatnagar S. Management of Wilms tumor: NWTS vs SIOP. J Indian Assoc Pediatr Surg 2009; 6-14
Lemerle J, Voute P.A, Tournade F, Rodary C, Delemarre J.F.M., Sarrazin D, et al. Effectiveness of Preoperative Chemotherapy in Wilms´ Tumor: Results of an International Society of Pediatric Oncology: Clinical Trial. JCO. 1983; 604-607.
Metzger M. Dome J. Current Therapy of Wilms Tumor. Oncologist 2005;10:815-826.
Pritchard Jones K, Bergeron C, Camargo B, Heuvel-Eibrink M, Cha T, Godzinki J, et al. Omission of doxorubicin from the treatment of stage II-III intermediaterisk Wilms Tumor (SIOP WT-2001): an open label, non inferiority, randomised controlled trial. Lancet 2015; 386: 1156-64.
Downloads
Published
Versions
- 2018-01-04 (2)
- 2018-01-04 (1)
Issue
Section
License
Copyright (c) 2018 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
